Pulse Pharma has received approval from the Drug Controller General of India (DCGI) for its nanocarrier Vitamin D3 technology, marking a significant regulatory milestone for the pharmaceutical company.

Key Facts

  • Company: Pulse Pharma
  • Regulatory Body: Drug Controller General of India (DCGI)
  • Technology: Nanocarrier Vitamin D3
  • Status: Approved

Regulatory Clearance

The approval from India's apex drug regulatory authority enables Pulse Pharma to proceed with its nanocarrier-based Vitamin D3 formulation. The DCGI clearance represents a critical step in bringing this advanced drug delivery technology to market.

Technology Overview

Nanocarrier technology represents an advanced approach to pharmaceutical delivery systems. The approval specifically covers the application of this technology to Vitamin D3 formulations, potentially offering improved bioavailability and targeted delivery compared to conventional methods.